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a  b  s  t  r  a  c  t
Heart  failure is  a typical  age-associated  disease.  However,  the  mechanism  by  which  heart  function
declines  and  heart  failure  increases  in  association  with  age  is not  clear.  Recent  advances  in  basic  sci-
ence  clarify  several  important  mechanisms  of aging.  The  mechanisms  identiﬁed  are  likely  to serve  as
substrates  by which  heart function  declines  and  predisposes  elderly  people  to  heart  failure.  One  sucheywords:
ging
eart failure
rotein homeostasis
nsulin
apamycin
mechanism  is insulin/insulin-like  growth  factor  (IGF)-1  signaling.  Suppression  of  insulin/IGF-1  signaling
prevents  cardiac  aging  associated  with  improved  protein  homeostasis  in  the  heart.  However,  the  role  of
insulin/IGF-1  signaling  in heart  diseases  is  likely  to  be  pleiotropic,  and both  protective  and  sensitizing
effects  have  been  described  in  different  contexts.  Reduction  in  function  of  extra-cardiac  organs  is  likely
to be  another  important  mechanism  by  which  heart  failure  increases  with  aging, since  heart  failure  is a
multiple  organ  system  disease.© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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The average life span is increasing, and the number of people
ged 65 and older is growing rapidly and will continue to increase
n the next 20 years. Among the elderly, cardiovascular disease
emains the leading cause of death. Heart failure (HF) in particular
s becoming a serious medical issue. Indeed, recent advances in the
iagnosis and treatment of HF have led to improved survival rates
1], but the number of patients with HF has been increasing and is
stimated to increase in future. In addition, HF is a major cause of
e-hospitalization [2].  For these reasons, HF consumes a signiﬁcant
mount of medical resources [3].
HF is a typical age-associated disease [4]. According to epidemi-
logical data from the USA, the prevalence of HF starts to increase
rom the age of 60 years, and most patients with HF are over 70
ears old. A recent epidemiological study in Japan also found that
ost HF patients are elderly [5].  In the USA, the prevalence of atrial
brillation (AF) is 3–4% in apparent healthy people over 60 years of
ge, 10 times higher than that in the younger population [4].
Although age is a major risk factor for cardiovascular diseases,
here are still many unanswered questions as to how advanced
ge predisposes people to cardiovascular disease. In this article, we
iscuss genetic mechanisms that have been identiﬁed to regulate
ging. Furthermore, we provide an overview of changes that occur
n the heart with age and the mechanism causing the age-related
hanges. Finally, we discuss the mechanism by which HF is a typical
ge-associated disease.
echanisms of aging
Until recently, studies of aging were mostly observational,
escribing changes in the morphology and function of tissues,
rgans, and organisms. However, two model systems have changed
esearch of aging, and the mechanisms of aging have been found.
ne of the systems is cellular senescence, which indicates that pri-
ary cultured cells have limited capacity for replication [6].  Cellular
enescence is characterized by a set of changes including increases
n cell cycle inhibitor expression and senescence-associated -
alactosidase activity [7].  Cellular senescence is also induced by
tress, such as oxidative stress and oncogene over expression. The
ther system is the genetic analysis of long-lived mutants of model
rganisms having a shorter life span, such as Caenorhabditis ele-
ans and Drosophila [8].  The mechanisms identiﬁed using these
ystems have been tested in mammals including genetically engi-
eered mice. The role of the pathways and molecules involved in
ging has also been tested in disease models.
aloric restriction
In 1935, McCay et al. reported that reducing a rat’s caloric intake
y 20–40% extends its life span [9].  Caloric restriction (CR) repro-
ucibly extends life-span in yeast, C. elegans,  and rodents. Caloric
estriction also prevents age-related diseases in monkeys [10].
mportantly, CR appears to simultaneously affect multiple genetic
athways involved in aging.
irtuins
Sirtuins are evolutionary conserved enzymes that function
s NAD+-dependent deacetylases and ribosyltransferases [11].
ammals have 7 sirtuins, which have a diverse distribution inhe cell and regulate a variety of cellular functions including
NA repair, the cell cycle, and metabolism. Sirtuins have been
bserved to modulate aging in yeast to mammals. SIRT1 is a yeast
omolog of Sir2, and the best-characterized sirtuin to date. Oncediology 60 (2012) 423–428
activated, SIRT1 displays pleiotropic effects, and both protective
and sensitizing effects have been described in disease models [11].
Insulin/insulin-like growth factor-1 signaling
A reduction in insulin signaling within an appropriate range
increases life span from C. elegans to mice [8].  Rapamycin,
which inhibits insulin/insulin-like growth factor (IGF)-1 signaling,
extends the life-span of mice [12]. Mutations that reduce the
activity of the IGF-I receptor protein were found in centenarians,
suggesting that insulin/IGF-1 signaling is involved in longevity in
humans [13].
Oxidative stress
Oxidative stress is known to damage proteins, lipids, and DNA,
and is hypothesized to be an important mechanism of aging [14].
Mitochondria are a major source of reactive oxygen species (ROS)
in the cell. Systemic overexpression of catalase in mitochondria
extends life-span in mice [15].
DNA damage
Damaged DNA accumulates in response to several factors
including oxidative stress and ultra-violet light. The damage acti-
vates p53, a representative tumor suppressor. Overexpression of
p53 induces cellular senescence. The constitutive activation of p53
causes premature senescence in mice [16]. Since p53 is a tumor sup-
pressor, senescence is considered a mechanism to prevent tumor
formation and to have a trade-off relation with cancer [17].
Protein homeostasis
Cellular homeostasis is maintained by the removal of damaged
proteins using the ubiquitin–proteasome system and autophagy,
and their replacement by newly synthesized proteins. In addition,
detoxiﬁcation protects cells from the toxic effects of damaged pro-
teins. Cells consume a signiﬁcant amount of ATP to maintain protein
homeostasis. Protein homeostasis is required for longevity induced
by CR [18].
Telomere
The telomere is a structure at the end of chromosomes that sta-
bilizes them. It becomes shorter with each cell division resulting
in cellular damage. Mice deﬁcient in telomerase show premature
aging [19].
Inﬂammation
Proinﬂammatory cytokines act as pro-senescence factors in
cellular senescence [20]. Since proinﬂammatory cytokines are
secreted from cells, they can regulate cellular senescence in
a non-cell-autonomous manner. Interestingly, proinﬂammatory
cytokines [21], or their major downstream target, nuclear factor
(NF)-B [22], act in a pro-aging manner in mice.
cAMPThe adenylate cyclase/protein kinase A (PKA) pathway is a
pro-aging pathway in yeast and mice [23,24].  However, the link
between this pathway and other mechanisms of aging is less clear.
 of Car
A
F
T
a
m
t
i
h
m
p
r
T
n
c
D
H
m
m
t
o
i
r
p
M
p
e
n
t
r
[
s
t
T
o
s
o
t
m
M
A
a
y
s
i
a
s
c
a
s
a
cT. Shioi, Y. Inuzuka / Journal
ge-related changes of cardiac function and morphology
unction
The age-associated change in cardiac function is as follows [4].
he heart rate, stroke volume, and cardiac output of elderly people
t rest do not differ from those in young people. Since heart rate at
aximal exercise is lower in the elderly, cardiac output in response
o exercise decreases although stroke volume is preserved.
Heart rate in response to maximum exercise starts to decrease
n middle age and continues to decline with aging. The decline of
eart rate during exercise is likely to limit exercise capacity from
iddle age. The decrease in cardiac functional reserve may  predis-
ose elderly people to HF. The mechanism by which heart rate in
esponse to maximum exercise changes during aging is not known.
he depletion of catecholamine in heart tissue, or impaired sig-
al transduction of beta-adrenergic receptors might explain the
hange [4].
Diastolic function of the heart assessed using left ventricular
oppler inﬂow patterns is known to decrease during aging [4].
owever, left ventricular diastolic function measured by Doppler
ethod is inﬂuenced by preload and after load, and so the approach
ay  not correctly reﬂect intrinsic diastolic function. Diastolic func-
ion is composed of active relaxation and passive stiffness. By use
f cardiac catheterization, it was found that relaxation was not
mpaired in the elderly [25]. Using magnetic resonance imaging,
elaxation was  shown to be decreased or unchanged in elderly
eople [26,27].
orphology
Heart weight increases with age under normal peripheral blood
ressure [4]. However, the size of cardiac myocytes increases in
lderly people although heart weight is normal, indicating that the
umber of cardiac myocytes in the heart decreases [28]. This con-
inued loss of functional cardiac cells is paralleled by a decline in
egenerative activity from 1% per year at age 20 to 0.4% at 75 years
29]. Interstitial ﬁbrosis of the myocardium is observed, which may
erve as a cause of arrhythmia, such as atrial ﬁbrillation. Accumula-
ion of lipofuscin and amyloid in cardiac myocytes is also observed.
he number of cells in the sino-atrial node decreases, and ﬁbrosis
f the atrio-ventricular node, His bundle, and cardiac conduction
ystem occurs.
Calciﬁcation of aortic valves or annuls of mitral valves is
bserved, and causes aortic stenosis and mitral stenosis, respec-
ively. Degeneration of mitral or tricuspid valves sometimes causes
itral regurgitation or tricuspid regurgitation.
olecular characterization of cardiac aging
ge-related changes of heart in mice
To examine age-related cardiac changes at the molecular level,
nd the mechanism causing the changes, we analyzed hearts from
oung (3 months old) and old (20 months old) mice [30]. Cardiac
ystolic function and diastolic function were preserved at rest, but
mpaired under dobutamine infusion. Heart weight increased with
n increase in cardiomyocyte cell size. Interstitial myocardial ﬁbro-
is was observed.
Cellular senescence is associated with the expression of
ell cycle inhibitors such as p53, p21, p16, and senescence-
ssociated -galactosidase activity [7].  The number of cells having
enescence-associated -galactosidase activity was  increased in
ged heart tissue. The expression of p16 and proinﬂammatory
ytokines was increased. The increased expression of markers ofdiology 60 (2012) 423–428 425
cellular senescence indicated that the mechanism of cardiomy-
ocyte senescence shares common mechanisms with cellular
senescence of cultured cells.
To examine the age-related changes of heart in an unbi-
ased manner, the gene expression proﬁle of heart tissue was
analyzed using whole-genome microarrays (Fig. 1). The biolog-
ical signiﬁcance of the gene expression proﬁling was examined
using a parametric analysis of gene set enrichment, a compu-
tational method that determines differences between pathways
using predeﬁned gene sets. The expression of genes involved in
inﬂammation was increased. The expression of genes involved in
protein homeostasis, such as protein folding and the ubiquitin
cycle, decreased with aging.
The dysregulation of genes involved in protein homeostasis was
associated with the accumulation of ubiqutinated protein in aged
heart. Poly-ubiqutinated proteins accumulated in cardiac myocytes
but not in interstitial cells, capillary arteries, or coronary arter-
ies. Lipofuscin is deﬁned as an autoﬂuorescent, undegradable, and
polymeric substance, primarily composed of cross-linked protein
and lipid residues. Lipofuscin is thought to be generated from
damaged protein. Post mitotic cells such as cardiac myocytes and
neurons accumulate a large amount of lipofuscin in old age [31].
On examination of tissue sections, lipofuscin autoﬂuorescence was
rarely observed in the myocardium of young mice, whereas a large
amount of lipofuscin was observed in old mice. Thus, impaired
protein homeostasis is a characteristic of cardiac aging.
HF as a degenerative disease
Accumulating evidence has indicated that impaired protein
homeostasis is involved in the development of HF [32]. Neuro-
degenerative diseases, such as Alzheimer’s disease, Huntington’s
disease, and Parkinson’s disease, are characterized by the accu-
mulation of abnormal inclusion bodies. Thus, impaired protein
homeostasis may  play a role in the HF seen in the elderly. Recently,
the accumulation of amyloid was  detected in patients with cardiac
amyloidosis using positron emission tomography [33].
Role of insulin/IGF-1 signaling in cardiac aging in mice
Insulin/IGF-1 signaling plays a critical role in aging [8].  Partic-
ularly, the reduction of insulin signaling in an appropriate range
increases life span in organisms ranging from C. elegans to mice.
Although the importance of the signaling in life-span regulation is
well established in lower organisms, there are still important ques-
tions to be answered. First, does the system work in an endocrine
manner or cell autonomous manner? Second, the downstream
mechanism by which the signaling regulates aging is still not clear.
Third, because the function of insulin signaling differs among tis-
sues, how the signaling regulates aging in individual organs also
needs to be examined.
The class IA isoform of phosphoinositide 3-kinase (PI3K) is
an important factor downstream of insulin and IGF-1 receptors,
and regulates cell growth, survival, and metabolism [34]. The
mammalian target of rapamycin (mTOR) is located downstream
of PI3K and rapamycin inhibits the activity of mTOR. We  have
examined the role of insulin/IGF-1 signaling by comparing the phe-
notype of old wild-type mice and old transgenic mice expressing
dominant-negative PI3K (dnPI3K) in a heart-speciﬁc manner [30].
Inhibition of PI3K prevented the expression of cellular senescence
markers and most of the age-related changes of gene expression
in the microarray analysis. Inhibition of PI3K also decreased
the accumulation of lipofuscin in heart tissue. Rapamycin pre-
vented the accumulation of lipofuscin with age. Autophagic ﬂux
was increased in dnPI3K. Moreover, chloroquine which inhibits
autophagic ﬂux increased the lipofuscin content of heart tissue.
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Fig. 1. Suppression of phosphoinositide 3-kianse (PI3K) prevented lipofuscin accumulation in aged heart tissue. (A) Frozen heart tissue sections were analyzed for lipofuscin
using  ﬂuorescence microscopy. The age-associated increase in autoﬂuorescence was attenuated in dnPI3K mice. Bars represent ±50 m. (B) Lipofuscin was extracted in a
chloroform–methanol mixture and evaluated in a ﬂuorescence spectroﬂuorimeter. Autoﬂuorescence at 485 nm was compared between the groups (n = 6 for each group).
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hus suppression of insulin/IGF-1 signaling prevented age-related
hanges of heart associated with improved protein homeostasis in
 cell-autonomous manner.
ther mechanisms involved in cardiac aging
CR prevented age-associated declines in cardiac function asso-
iated with reduced suppressed mTOR signaling and increased
utophagy in rats [35]. Systemic deletion of the angiotensin type
 receptor or adenyl cyclase 5 prevented age-associated changes of
eart [24,36]. Also, systemic overexpression of catalase targeting
itochondria prevented cardiac aging [37].
ontext-dependent role of insulin signaling
Life-long inhibition of PI3K prevented cardiac aging. More-
ver, dnPI3K mice did not develop cardiac dysfunction in response
o acute ischemia reperfusion [38]. These results are consistent
ith the hypothesis established in model organisms with a short
ife-span that reduced insulin/IGF-1 signaling increases stress resis-
ance and extends life-span.p < 0.05 versus younger mice of the same genotype. p < 0.05 versus WT mice of the
However, PI3K is necessary and sufﬁcient to maintain systolic
function under pressure overload induced by aortic constriction
[39,40].  Moreover, cardiac systolic function in response to dobut-
amine was  impaired in the young dnPI3K mice [30]. Mitochondrial
function is impaired in the dnPI3K mouse [41].
The apparent paradoxical response of the hearts of dnPI3K mice
to different stimuli is likely because different downstream effec-
tors of PI3K work for different durations and types of stress. For
example, improved protein homeostasis is likely to prevent car-
diac aging. On the other hand, a decrease in mitochondrial function
may  cause impaired cardiac function in response to dobutamine
and pressure overload.
Pathogenesis of cardiovascular diseases share common
mechanisms with those of aging
Many cardiovascular diseases are associated with age. One rea-
son for this is likely to be that an advanced age increases the
chance of exposure to cardiovascular risk factors. However, age-
associated intrinsic changes to the cardiovascular system may also
compromise the cardiovascular reserve capacity and decrease the
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Fig. 2. Mechanisms of cardiovascular diseases share common mechanisms with
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Hging. The mechanisms of aging, such as oxidative stress, insulin signaling, protein
omeostasis, and inﬂammation, are involved in the pathogenesis of cardiovascular
iseases.
hreshold for primary diseases to manifest. It is also possible that
he age-associated changes serve as a basis of primary diseases.
ndeed, the mechanisms of aging, such as oxidative stress, insulin
ignaling, protein homeostasis, and proinﬂammatory response, are
nown to be involved in the pathogenesis of cardiovascular dis-
ases (Fig. 2).
F as a multiple organ system disease
Among the cardiovascular diseases, HF is a typical age-
ssociated disease and the number of patients with HF increases
xponentially with aging. Why  does the number of patients with
F increase exponentially in relation to age? One reason is likely to
e that the development of HF involves multiple organs other than
ig. 3. Heart failure (HF) as a multiple organ system disease. The functional reserve
f the heart decreases with aging via multiple mechanisms including insulin/insulin-
ike  growth factor-1 signaling. The decrease in functional capacity increases the
hance of developing HF in response to heart diseases such as myocardial ischemia
nd hypertension. Since the development and progression of HF involve multiple
xtra-cardiac organs, such as lung, kidney, liver, adipose tissue, and skeletal muscle,
he age-associated decline in the function of these extra-cardiac organs is likely to
ower the threshold for HF development. In addition, diseases of these extra-cardiac
rgans, such as chronic obstructive pulmonary disease (COPD), chronic kidney dis-
ase (CKD), diabetes mellitus (DM), and cachexia, further worsen the prognosis of
F.
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the heart, such as the lungs, kidneys, and skeletal muscle (Fig. 3).
The decline in functional reserve in these organs may  be involved
in the development of HF in aged populations. It would be worth
examining how the decline in the function of extra-cardiac organs
affects the development of HF. It is also necessary to explore how a
decline in heart function or HF affects the function of extra-cardiac
organs.
Future perspectives
Aging may  serve as a basis of other cardiovascular risk factors
and also the cardiovascular diseases themselves. Thus, understand-
ing the mechanism of cardiovascular aging may overcome all other
risk factors collectively, and could lead to signiﬁcant advancements
in both preventative and therapeutic treatments for cardiovascular
diseases.
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